AML (Acute Myeloid Leukemia)

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

HMA-Venetoclax Induction in Newly Diagnosed AML

PRAISE-IR Versus CIBMTR Controls

A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients

DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML

Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells

CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML

Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML

Haplo-Cord HSCT for AML/MDS

Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

FLT3-ITD Targeted Therapy in Fit AML Patients

Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia

Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML

Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML

Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX